Rodman David Malcom Acquires Shares in Mineralys Therapeutics
The Chief Medical Officer added 4,584 shares of Mineralys Therapeutics on June 17, 2026.
Key Points
- Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics, purchased 4,584 shares valued at $65,818.45 on June 17, 2026.
- Mineralys Therapeutics, Inc. trades on the NasdaqGS with a market cap of $2.11 billion and a beta of 0.565.
- Analysts maintain a strong buy consensus on Mineralys with a mean price target of $49.00.
Rodman David Malcom, the Chief Medical Officer of Mineralys Therapeutics, Inc. (NasdaqGS: MLYS), recently purchased 4,584 shares of the company. This insider buying, executed on June 17, 2026, was valued at approximately $65,818.45, with an average purchase price of $14.36 per share.
Insider Buying and Selling at Mineralys Therapeutics, Inc.
On June 17, 2026, Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics, bought 4,584 shares at an average price of $14.36, totaling around $65,818.45. This transaction was not part of a pre-planned trading program. Daphne Karydas, another insider, also reported transactions on the same date, including a planned sale of 3,000 shares at $25.00 per share.
Other Institutional Activity in Mineralys Therapeutics
Several institutional investors have also been active in Mineralys Therapeutics. RA Capital Management, L.P. increased its holdings by 369,000 shares, bringing its total to 7,692,750 shares, valued at about $208.4 million. Wellington Management Group LLP made a significant addition of 2,574,801 shares, now holding 3,359,068 shares worth approximately $90.9 million. Meanwhile, FMR LLC trimmed its position by 196,405 shares, leaving it with 4,861,104 shares valued at roughly $131.7 million.
Mineralys Therapeutics Stock Snapshot
Shares of Mineralys Therapeutics, Inc. (NasdaqGS: MLYS) are trading around $23.99. The company has a market capitalization of approximately $2.11 billion and a beta of 0.565, indicating lower volatility relative to the market. The stock's 52-week range is between $12.59 and $47.65, with a 50-day moving average of $27.72 and a 200-day moving average of $33.07. Mineralys has a current ratio of 44.33 and a quick ratio of 43.90, reflecting strong liquidity.
Analysts Set New Price Targets
Several analysts have maintained their ratings for Mineralys Therapeutics. On March 13, 2026, B of A Securities upheld a 'buy' rating with a price target of $51.00. Stifel, HC Wainwright & Co., and Wells Fargo have also maintained 'buy' ratings with targets ranging from $50.00 to $56.00. Overall, the consensus among analysts is a 'strong buy', with a mean price target of $49.00 based on eight opinions.
About Mineralys Therapeutics
Mineralys Therapeutics, Inc. is a biotech company based in Radnor, Pennsylvania, focusing on developing treatments for diseases driven by dysregulated aldosterone, such as hypertension and chronic kidney disease. The company's lead product, lorundrostat, is an orally administered inhibitor targeting aldosterone synthase. Established in 2019, Mineralys is led by CEO Dr. Jon Congleton and employs 76 people.
Bottom Line
Rodman David Malcom's purchase of Mineralys shares reflects insider confidence in the company's prospects. Investors often watch insider transactions for insights into a company's future. While 13F filings and insider trades provide historical data, they may not represent current positions. Analysts remain optimistic about Mineralys, maintaining strong buy ratings and high price targets.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.